Echodyne and Moog Successfully Demonstrate Reconfigurable Integrated-weapon Platform (RIwP®) at U.S. Army Exercise
19.5.2026 15:00:00 CEST | Business Wire | Press Release
Echodyne, the radar platform company, and Moog Inc. (NYSE: MOG.A and MOG.B), a worldwide designer, manufacturer, and systems integrator of high performance precision motion and control systems, announce the results of testing of their defensive systems to counter small offensive UAS (“sUAS”) weapons.
Capabilities Tested
- Live detection, lock on with precision tracking, and successfully engaging of Group 1-3 UAS threats in less than 3 seconds.
- Combined AI targeting, wireless fire control, and radar integration across mission equipment capabilities for defense against small UAS weapons.
- AI targeting for passive detection, autonomous targeting, track re-acquire, multi-object targeting.
Outputs
- Identified and swiftly rectified critical capability gaps within a simulated battlefield environment.
- Proved that combining precision data with AI firing solution computation is a cost-effective solution for rapidly upgrading existing kinetic weapon stations to highly effective C-UAS systems.
One of today’s critical Defense challenges is detecting, tracking, and mitigating small unmanned offensive platforms in all domains. The speed and lethality of sUAS means they are a constant and serious threat on the battlefield, requiring rapid systems response to protect the warfighter.
The Operation Condor Rebirth demonstration exercise was conducted at Fort Hood, Texas in late March and the team included Moog (RIwP and AI targeting), Echodyne (EchoShield radar), and Picogrid (Legion data platform for connected mission systems). The goal was to deliver rapid integration of new systems into a secure Army network and validate against simulated threats in live-fire scenarios.
Moog’s modular weapons platform includes an edge computer, Echodyne’s EchoShield radar for precision tracking, and cables to enable integration with any existing U.S. Army turreted weapon station. The AI targeting system is an enhanced counter-UAS (C-UAS) detection and tracking capability designed for turreted weapons. Fusing precision airspace data with AI capabilities for rapid firing solution computation shown to immediately upgrade these existing kinetic weapon stations to effective C-UAS systems. The team demonstrated detecting, locking on with solid precision tracking, and successfully engaging Group 1-3 UAS threats in less than 3 seconds.
EchoShield is the market-leading medium range radar that consistently and reliably generates precise location data for all drone types and configurations. As a commercial-off-the-shelf (COTS) radar system, EchoShield’s industry standard interfaces and rich data options create a baseline data set that accurately slews optical sensors, cues effector options, and accelerates reaction time. Boasting advanced classification capabilities built on advanced machine learning models, EchoShield tracks all movement and pinpoints system and operator attention where and when it matters.
“Echodyne is proud to continue supporting Moog’s advanced C-UAS and Air Defense capabilities as a trusted partner and collaborator,” said Eben Frankenberg, Echodyne CEO. “By combining high quality radar sensors and rapid integration of data it is possible to deliver impressive C-UAS capabilities from existing battlefield systems, affordably and more quickly than using purpose-built systems.”
“This is a critical moment to rapidly strengthen C-UAS defenses and protect warfighters against evolving threats,” said Mike Gruver, Moog SVP Defense. “Working with teammates like Echodyne ensures the best forms of C-UAS capabilities are available to the U.S. and its Allies.”
About Echodyne
Echodyne, the radar platform company, is a U.S. designer and manufacturer of high-performance radar systems for defense, government, and commercial market applications. The company combines patented metamaterials electronically scanned array (MESA®) technology with powerful software and machine learning to deliver high-fidelity situational awareness data pinpointing activity in air and surface domains with unrivalled speed, accuracy, and precision. Proven and trusted by militaries, agencies, integrators, and critical infrastructure around the globe, Echodyne’s products set a new standard for commercial high-fidelity radar excellence. Privately held, the company is headquartered in Kirkland, WA, USA and backed by Bill Gates, NEA, Madrona Venture Group, Baillie Gifford, and Northrop Grumman, among others. See radar in action at echodyne.com or call +1-425-753-7015.
About Moog Inc.
Moog is a worldwide designer, manufacturer, and systems integrator of high-performance precision motion and fluid controls and control systems. Moog’s high-performance systems control military and commercial aircraft, satellites, and space vehicles, launch vehicles, defense systems, missiles, automated industrial machinery, marine and medical equipment. Additional information can be found at www.moog.com or www.moog.com/defense.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260519187657/en/
Contacts
Media and Business Development
Defense Marketing Team
defensemedia@moog.com
Investor Relations
Aaron Astrachan
+1 716.687.4225
investorrelations@moog.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press Release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press Release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom